Cargando…

High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia

BACKGROUND: Long-term outcomes of antiretroviral therapy (ART) in children remain poorly documented in resource-limited settings. The objective of this study was to assess two-and three-year survival, CD4 evolution and virological response among children on ART in a programmatic setting in Cambodia....

Descripción completa

Detalles Bibliográficos
Autores principales: Isaakidis, Petros, Raguenaud, Marie-Eve, Te, Vantha, Tray, Chhraing S, Akao, Kazumi, Kumar, Varun, Ngin, Sopheak, Nerrienet, Eric, Zachariah, Rony
Formato: Texto
Lenguaje:English
Publicado: The International AIDS Society 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851581/
https://www.ncbi.nlm.nih.gov/pubmed/20302672
http://dx.doi.org/10.1186/1758-2652-13-11
_version_ 1782179876235640832
author Isaakidis, Petros
Raguenaud, Marie-Eve
Te, Vantha
Tray, Chhraing S
Akao, Kazumi
Kumar, Varun
Ngin, Sopheak
Nerrienet, Eric
Zachariah, Rony
author_facet Isaakidis, Petros
Raguenaud, Marie-Eve
Te, Vantha
Tray, Chhraing S
Akao, Kazumi
Kumar, Varun
Ngin, Sopheak
Nerrienet, Eric
Zachariah, Rony
author_sort Isaakidis, Petros
collection PubMed
description BACKGROUND: Long-term outcomes of antiretroviral therapy (ART) in children remain poorly documented in resource-limited settings. The objective of this study was to assess two-and three-year survival, CD4 evolution and virological response among children on ART in a programmatic setting in Cambodia. METHODS: Children treated with first-line ART for at least 24 months were assessed with viral load testing and genotyping. We used Kaplan-Meier analysis for survival and Cox regression to identify risk factors associated with treatment failure. RESULTS: Of 1168 registered HIV-positive children, 670 (57%) started ART between January 2003 and December 2007. Survival probability was 0.93 (95% CI: 0.91-0.95) and 0.91 (95% CI: 0.88-0.93) at 24 and 36 months after ART initiation, respectively. Median CD4 gain for children aged over five years was 704 cells/mm(3 )at 24 months and 737 at 36 months. Median CD4 percentage gain for children under five years old was 15.2% at 24 months and 15% at 36 months. One hundred and thirty children completed at least 24 months of ART, and 138 completed 36 months: 128 out of 268 (48%) were female. Median age at ART initiation was six years. Overall, 22 children had viral loads of >1000 copies/ml (success ratio = 86% on intention-to-treat-analysis) and 21 of 21 presented mutations conferring resistance mostly to lamivudine and non-nucleoside reverse transcriptase inhibitors. Risk factors for failure after 24 and 36 months were CD4 counts below the threshold for severe immunosupression at those months respectively. Only two out of 22 children with viral loads of >1000 copies/ml met the World Health Organization immunological criteria for failure (sensitivity = 0.1). CONCLUSIONS: Good survival, immunological restoration and viral suppression can be sustained after two to three years of ART among children in resource-constrained settings. Increased access to routine virological measurements is needed for timely diagnosis of treatment failure.
format Text
id pubmed-2851581
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher The International AIDS Society
record_format MEDLINE/PubMed
spelling pubmed-28515812010-04-09 High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia Isaakidis, Petros Raguenaud, Marie-Eve Te, Vantha Tray, Chhraing S Akao, Kazumi Kumar, Varun Ngin, Sopheak Nerrienet, Eric Zachariah, Rony J Int AIDS Soc Research BACKGROUND: Long-term outcomes of antiretroviral therapy (ART) in children remain poorly documented in resource-limited settings. The objective of this study was to assess two-and three-year survival, CD4 evolution and virological response among children on ART in a programmatic setting in Cambodia. METHODS: Children treated with first-line ART for at least 24 months were assessed with viral load testing and genotyping. We used Kaplan-Meier analysis for survival and Cox regression to identify risk factors associated with treatment failure. RESULTS: Of 1168 registered HIV-positive children, 670 (57%) started ART between January 2003 and December 2007. Survival probability was 0.93 (95% CI: 0.91-0.95) and 0.91 (95% CI: 0.88-0.93) at 24 and 36 months after ART initiation, respectively. Median CD4 gain for children aged over five years was 704 cells/mm(3 )at 24 months and 737 at 36 months. Median CD4 percentage gain for children under five years old was 15.2% at 24 months and 15% at 36 months. One hundred and thirty children completed at least 24 months of ART, and 138 completed 36 months: 128 out of 268 (48%) were female. Median age at ART initiation was six years. Overall, 22 children had viral loads of >1000 copies/ml (success ratio = 86% on intention-to-treat-analysis) and 21 of 21 presented mutations conferring resistance mostly to lamivudine and non-nucleoside reverse transcriptase inhibitors. Risk factors for failure after 24 and 36 months were CD4 counts below the threshold for severe immunosupression at those months respectively. Only two out of 22 children with viral loads of >1000 copies/ml met the World Health Organization immunological criteria for failure (sensitivity = 0.1). CONCLUSIONS: Good survival, immunological restoration and viral suppression can be sustained after two to three years of ART among children in resource-constrained settings. Increased access to routine virological measurements is needed for timely diagnosis of treatment failure. The International AIDS Society 2010-03-21 /pmc/articles/PMC2851581/ /pubmed/20302672 http://dx.doi.org/10.1186/1758-2652-13-11 Text en Copyright ©2010 Isaakidis et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Isaakidis, Petros
Raguenaud, Marie-Eve
Te, Vantha
Tray, Chhraing S
Akao, Kazumi
Kumar, Varun
Ngin, Sopheak
Nerrienet, Eric
Zachariah, Rony
High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia
title High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia
title_full High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia
title_fullStr High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia
title_full_unstemmed High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia
title_short High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia
title_sort high survival and treatment success sustained after two and three years of first-line art for children in cambodia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851581/
https://www.ncbi.nlm.nih.gov/pubmed/20302672
http://dx.doi.org/10.1186/1758-2652-13-11
work_keys_str_mv AT isaakidispetros highsurvivalandtreatmentsuccesssustainedaftertwoandthreeyearsoffirstlineartforchildrenincambodia
AT raguenaudmarieeve highsurvivalandtreatmentsuccesssustainedaftertwoandthreeyearsoffirstlineartforchildrenincambodia
AT tevantha highsurvivalandtreatmentsuccesssustainedaftertwoandthreeyearsoffirstlineartforchildrenincambodia
AT traychhraings highsurvivalandtreatmentsuccesssustainedaftertwoandthreeyearsoffirstlineartforchildrenincambodia
AT akaokazumi highsurvivalandtreatmentsuccesssustainedaftertwoandthreeyearsoffirstlineartforchildrenincambodia
AT kumarvarun highsurvivalandtreatmentsuccesssustainedaftertwoandthreeyearsoffirstlineartforchildrenincambodia
AT nginsopheak highsurvivalandtreatmentsuccesssustainedaftertwoandthreeyearsoffirstlineartforchildrenincambodia
AT nerrieneteric highsurvivalandtreatmentsuccesssustainedaftertwoandthreeyearsoffirstlineartforchildrenincambodia
AT zachariahrony highsurvivalandtreatmentsuccesssustainedaftertwoandthreeyearsoffirstlineartforchildrenincambodia